Christine Bestvina, MD
Within the last decade, 4 tyrosine kinase inhibitors (TKIs) have been approved for the frontline treatment of patients with EGFR
-positive non–small cell lung cancer (NSCLC). However, in recent years, both investigators and patients have been curious about the potential for immunotherapy. This should not underscore the successes of agents such as osimertinib (Tagrisso), though, said Christine Bestvina, MD.
... to read the full story